Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Jasper Therapeutics Q1 EPS $(1.03) Beats $(1.23) Estimate

Author: Benzinga Newsdesk | May 14, 2024 08:35am
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.23) by 16.26 percent. This is a 35.63 percent increase over losses of $(1.60) per share from the same period last year.

Posted In: JSPR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist